|
摘要：
|
|
摘要：目的 探讨丙型肝炎病毒核心蛋白结合蛋白6（hepatitis C virus core-binding protein 6，HCBP6）
在脂肪性肝病患者中的表达及意义。方法 收集2019年8月至2020年2月首都医科大学附属北京地坛医
院确诊的30例脂肪性肝病患者为研究对象，其中酒精性脂肪性肝病（alcoholic liver disease，ALD）组
10例，非酒精性脂肪性肝病（non-alcoholic fatty liver disease，NAFLD）组20例，另选取30例同期健
康体检者为正常对照组。采用全自动生化分析仪检测血清生物化学指标，包括：丙氨酸氨基转移酶
（alanine aminotransferase，ALT）、天门冬氨酸基转移酶（aspartate aminotransferase，AST）、总胆红
素（total bilirubin，TBil）、直接胆红素（direct bilirubin，DBil）、总胆固醇（cholesterol，CHOL）和
甘油三酯（triglyceride，TG）。采用Western blot和酶联免疫吸附试验（enzyme linked immunosorbent
assay，ELISA）检测血清HCBP6水平。结果 脂肪性肝病组患者ALT [（80.16 ± 21.26）U/L vs（29.20 ±
3.58）U/L]、AST [（97.10 ± 20.76）U/L vs（46.30 ± 4.52）U/L]、CHOL [（4.41 ± 0.09）mmol/L vs（3.77 ±
0.08）mmol/L]和TG [（1.92 ± 0.08）mmol/L vs（1.48 ± 0.03）mmol/L]水平均显著高于正常对照组，
差异有统计学意义（P均＜ 0.05），TBil [（91.11 ± 25.75）μmol/L vs（42.90 ± 7.50）μmol/L]和DBil
[（65.23 ± 20.12）μmol/L vs（26.14 ± 5.01）μmol/L]差异无统计学意义（P均＞ 0.05）。NAFLD组、
ALD组及正常对照组ALT [（70.25 ± 18.24）U/L vs（99.98 ± 53.82）U/L vs（29.20 ± 3.58）U/L]、AST
[（91.35 ± 26.09）U/L vs（98.60 ± 35.93）U/L vs（46.30 ± 4.52）U/L]、CHOL [（4.56 ± 0.10）mmol/L vs
（4.12 ± 0.11）mmol/L vs（3.77 ± 0.08）mmol/L]和TG [（1.97 ± 0.02）mmol/L vs（1.81 ± 0.09）mmol/L
vs（1.48 ± 0.03）mmol/L]水平差异有统计学意义（P均＜ 0.05），TBil [（97.34 ± 34.91）μmol/L vs
（78.67 ± 35.21）μmol/L vs（42.90 ± 7.50）μmol/L]和DBil [（69.34 ± 27.35）μmol/L vs（57.01 ±
27.24）μmol/L vs（26.14 ± 5.01）μmol/L]差异无统计学意义（P均＞ 0.05）。其中，NAFLD组和ALD
组ALT、AST、CHOL和TG水平均显著高于正常对照组（P均＜ 0.05）；NAFLD组CHOL水平显著高于
ALD组（t = 2.681，P = 0.012），两组患者ALT、AST和TG水平差异无统计学意义（P均＞ 0.05）。脂
肪性肝病组患者血清HCBP6水平显著低于正常对照组 [（0.46 ± 0.02）μg/L vs（0.67 ± 0.03）μg/L]，差
异有统计学意义（t = 5.737，P ＜ 0.001）。NAFLD组、ALD组及正常对照组血清HCBP6水平 [（0.46 ±
0.02）μg/L vs（0.47 ± 0.03）μg/L vs（0.67 ± 0.03）μg/L] 差异有统计学意义（F = 16.190，P ＜ 0.001），
与正常对照组相比，NAFLD组和ALD组患者HCBP6水平均显著降低（t = 4.871，P ＜ 0.001；t =
3.520，P = 0.001）。结论 HCBP6在脂肪性肝病患者，尤其是NAFLD患者外周血中呈低表达。
|
|
Abstract: Objective To investigate the expression and clinical significance of hepatitis C virus core-binding
protein 6 (HCBP6) in patients with fatty liver disease. Methods A total of 30 patients with fatty liver disease
in Beijing Ditan Hospital, Capital Medical University from August 2019 to February 2020 were selected,
including 10 cases in alcoholic fatty liver (ALD) group and 20 cases in non-alcoholic fatty liver disease
(NAFLD) group. Another 30 healthy subjects were collected as normal control group. Automatic biochemical
analyzer was used to detect the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase
(AST), total bilirubin (TBil), direct bilirubin (DBil), cholesterol (CHOL) and triglyceride (TG). Western blot
and enzyme linked immunosorbent assay (ELISA) were used to detect the serum level of HCBP6. Results ALT
[(80.16 ± 21.26) U/L vs (29.20 ± 3.58) U/L], AST [(97.10 ± 20.76) U/L vs (46.30 ± 4.52) U/L], CHOL [(4.41 ±
0.09) mmol/L vs (3.77 ± 0.08) mmol/L] and TG [(1.92 ± 0.08) mmol/L vs (1.48 ± 0.03) mmol/L] levels of
patients in fatty liver group were significantly higher than those of normal control group (all P ＜ 0.05), and
there were no significant difference in TBil [(91.11 ± 25.75) μmol/L vs (42.90 ± 7.50) μmol/L] and DBil [(65.23 ±
20.12) μmol/L vs (26.14 ± 5.01) μmol/L] (all P ＞ 0.05). There were significant differences in ALT [(70.25 ±
18.24) U/L vs (99.98 ± 53.82) U/L vs（29.20 ± 3.58）U/L], AST [(91.35 ± 26.09) U/L vs (98.60 ± 35.93) U/L vs
(46.30 ± 4.52) U/L], CHOL [(4.56 ± 0.10) mmol/L vs (4.12 ± 0.11) mmol/L vs (3.77 ± 0.08) mmol/L] and
TG [(1.97 ± 0.02) mmol/L vs (1.81 ± 0.09) mmol/L vs (1.48 ± 0.03) mmol/L] levels of patients in NAFLD
group, ALD group and normal control group (all P ＜ 0.05), and there were no significant differences in TBil
[(97.34 ± 34.91) μmol/L vs (78.67 ± 35.21) μmol/L vs (42.90 ± 7.50) μmol/L]and DBil [(69.34 ± 27.35) μmol/L vs
(57.01 ± 27.24) μmol/L vs (26.14 ± 5.01) μmol/L] (all P ＞ 0.05). ALT, AST, CHOL and TG levels of patients
in NAFLD group and ALD group were significantly higher than those of normal control group (all P ＜ 0.05).
The CHOL level of patients in NAFLD group was significantly higher than that of ALD group (t = 2.681,
P = 0.012), and there were no significant differences in ALT, AST and TG levels between the two groups (all
P ＞ 0.05). Serum HCBP6 level of patients in fatty liver group was significantly lower than that of normal control
group [(0.46 ± 0.02) μg/L vs (0.67 ± 0.03) μg/L], the difference was statistically significant (t = 5.737, P ＜
0.001). Serum HCBP6 levels of patients in NAFLD group, ALD group and normal control group [(0.46 ±
0.02) μg/L vs (0.47 ± 0.03) μg/L vs (0.67 ± 0.03) μg/L] were statistically significant (F = 16.190, P ＜ 0.001).
The serum HCBP6 level of patients in NAFLD group and ALD group were significantly lower than that of
normal control group (t = 4.871, P ＜ 0.001; t = 3.520, P = 0.001). Conclusions HCBP6 is lowly expressed in
the peripheral blood of patients with fatty liver disease, especially patients with NAFLD.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|